Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits

References

• Hepler R. S., Frank M. Marihuana smoking and intraocular pressure. J. Amer. Med. Ass. 1971; 217: 1392
   PubMed Web of Science ®Google Scholar
• Merritt J. C., McKinnon S., Armstrong J. R., Hatem G., Reid L. A. Oral delta-9-tetrahydrocannabinol in heterogeous glaucomas. Annals of Ophthalmol. 1980; 12: 947–950
   Web of Science ®Google Scholar
• Cooler P., Gregg J. M. Effect of delta-9-tetrahydrocannabinol on intraocular pressure in humans. South Med. J. 1977; 70: 951–954
   PubMed Web of Science ®Google Scholar
• Merritt J. G., Whitaker R., Page C. J., Peace J. H., Grimson R. C., Olsen J. L., Peiffer R. L., Davanzo R. Topical delta-8-tetrahydrocannabinol as a potential glaucoma agent. Glaucoma 1982; 4: 253–255
   Google Scholar
• Green K., Symonds C. M., Oliver N. W., Elijah R. D. Intraocular pressure following systemic administration of cannabinoids. Curr. Eye Res. 1983; 2: 247–253
   Web of Science ®Google Scholar
• Colasanti B. K., Powell S. R., Craig C. R. Intraocular pressure, ocular toxicity and neurotoxicity after administration of delta-9-tetrahydrocannabinol or cannabichromene. Exp. Eye Res. 1984; 38: 63–71
   PubMed Web of Science ®Google Scholar
• ElSohly M. A., Harland E. C., Benigni D. A., Waller C. W. Cannabinoids in glaucoma II: The effect of different cannabinoids on intraocular pressure on the rabbit. Curr. Eye Res. 1984; 3: 841–850
   PubMed Web of Science ®Google Scholar
• Colasanti B. K. A comparison of the ocular and central effects of delta-9-tetrahydrocannabinol and cannabigerol. J. Ocul. Pharmacol. 1990; 6: 259–269
   PubMedGoogle Scholar
• Muchtar S., Almog S., Torracca M. T., Saettone M. F., Benita S. A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits. Ophthalmic Res. 1992; 24: 142–149
   PubMed Web of Science ®Google Scholar
• Devane W. A., Dysarz F. A., Johnson M. R., Melvin L. S., Howlett A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 1988; 34: 605–613
   PubMed Web of Science ®Google Scholar
• Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946–1949
   PubMed Web of Science ®Google Scholar
• Hanus L., Gopher A., Almong S., Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 1993; 36: 3032–3034
   PubMed Web of Science ®Google Scholar
• Felder C. C., Briley E. M., Axelrod J., Simpson J. T., Mackie K., Devane W. A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. 1993; 90: 7656–7660
   PubMed Web of Science ®Google Scholar
• Abadji V., Lin S., Taha G., Griffin G., Stevenson L. A., Pertwee R. G., Makriyannis A. (R)-Methanandamide: A Chiral Novel Anandamide Possessing Higher Potency and Metabolic Stability. J. Med. Chem. 1994; 37: 1889–1893
   PubMed Web of Science ®Google Scholar
• Munro S., Thomas K. L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61–65
   PubMed Web of Science ®Google Scholar
• Uekama K., Otagiri M. Cyclodextrins in drug carrier systems. CRC Crit. Rev. Then Drug Carrier Syst. 1987; 3: 1–41
   PubMed Web of Science ®Google Scholar
• Bekers O., Uijtendaal E. V., Beijnen J. H., Bult A., Underberg W. J. M. Cyclodextrins in the pharmaceutical field. Drug Dev. Ind. Pharm. 1991; 17: 1503–1549
   Web of Science ®Google Scholar
• Jansen T., Xhonneux B., Mesens J., Borgers M. Beta-cyclodextrins as vehicles in eye-drop formulations: An evaluation of their effects on rabbit corneal epithelium. Lens Eye Toxicity Res. 1990; 7: 459–468
   PubMedGoogle Scholar
• Freedman K. A., Klein J. W., Crosson C. E. Beta-cyclodextrins enhance bioavailability of pilocarpine. Curr. Eye Res. 1993; 12: 641–647
   PubMed Web of Science ®Google Scholar
• Green K., Podos S. M. Antagonism of arachidonic acid-induced ocular effects by Δ1-tetrahydrocannabinol. Invest. Ophthalmol. Vis. Sci. 1974; 13: 422–429
   Google Scholar
• Lee P., Podos S. M., Severin C. Effect of prostaglandin F2α on aqueous humor dynamics of rabbit, cat, and monkey. Invest. Opthalmol. Vis. Sci. 1984; 25: 1087–1093
   PubMed Web of Science ®Google Scholar
• Sugrue M. F. The pharmacology of antiglaucoma drugs. Pharmac. Ther. 1989; 43: 91–138
   PubMed Web of Science ®Google Scholar
• Vartiainen J., MacDonald E., Urtti A., Rouhiainen H., Virtanen R. Dexmedetomidine-induced ocular hypotension in rabbits with normal or elevated intraocular pressures. Invest. Ophthalmol. Vis. Sci. 1992; 33: 2019–2023
   PubMed Web of Science ®Google Scholar
• Potter D. E., Ogidigben M. J. Medetomedine-induced alterations of intraocular pressure and contraction of the nictitating membrane. Invest. Ophthalmol. Vis. Sci. 1991; 32: 2799–2805
   PubMed Web of Science ®Google Scholar
• Crosson C. E. Ocular hypotensive activity of the adenosine agonist (R)-phenylisopropyladenosine in rabbits. Curr. Eye Res. 1992; 11: 453–458
   PubMed Web of Science ®Google Scholar
• Crosson C. E., Gray T. Modulation of intraocular pressure by adenosine agonists. J. Ocul. Pharmacol. 1994; 10: 379–383
   PubMedGoogle Scholar
• Chang S. C., Lee V. H. L. Nasal and conjunctival contributions to the systemic absorption of topical timolol in the pigmented rabbit: implications in the design of strategies to maximize the ratio of ocular to systemic absorption. J. Ocul. Pharmacol. 1987; 3: 159–169
   PubMedGoogle Scholar
• Urtti A., Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv. Ophthalmol. 1993; 37: 435–457
   PubMed Web of Science ®Google Scholar
• Salminen L., Urtti A. Disposition of ophthalmic timolol in treated and untreated rabbit eyes. A multiple and single dose study. Exp. Eye Res. 1984; 38: 203–206
   PubMed Web of Science ®Google Scholar
• Urtti A., Salminen L. A comparison between iris-ciliary body concentration and receptor affinity of timolol. Acta Ophthalmol. 1985; 63: 16–18
   Web of Science ®Google Scholar
• Järvinen K., Järvinen T., Thompson D. O., Stella V. J. The effect of a modified β-cyclodextrin, SBE4-β-CD, on the aqueous stability and ocular absorption of pilocarpine. Curr. Eye Res. 1994; 13: 891–905
   PubMed Web of Science ®Google Scholar
• Järvinen T., Järvinen K., Urtti A., Thompson D. O., Stella V. J. Sulfobutylether (βJ-cyclodextrin (SBE4-β-CD) in eyedrops improves the tolerability of a topically applied pilocarpine prodrugs in rabbits. J. Ocul. Pharmacol. 1994, in press
   Google Scholar
• Loftsson T., Fridriksdóttir H., Thórisdóttir S., Stefánsson E., Sigurdardóttir A. M., Gudmundsson Ö., Sigthórsson T. 2-Hydroxypropyl-β-cyclodextrin in topical carbonic anhydrase inhibitor formulations. Eur. J. Pharm. Sci. 1994; 1: 175–180
   Web of Science ®Google Scholar
• Frijlink H. W., Eissens A. C., Schoonen A. J. M., Lerk C. F. The effects of cyclodextrins on drug absorption. II. In vivo observation. Int. J. Pharm. 1990; 64: 195–205
   Web of Science ®Google Scholar
• Nakanishi K., Masada M., Nadai T., Miyajima K. Effect of the interaction of drug-β-cyclodextrin complex with bile salts on the drug absorption from rat small intestinal lumen. Chem. Pharm. Bull. 1989; 37: 211–214
   PubMed Web of Science ®Google Scholar
• Novack G. Ophthalmic beta-blockers since timolol. Surv. Ophthalmol. 1987; 31: 307–327
   PubMed Web of Science ®Google Scholar